samedan logo
 
 
spacer
home > pmps > spring 2004 > injectables and the competitive edge
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Injectables and the Competitive Edge

Taken from a marketing point of view, injectable therapeutics pose a challenge, for in these products there lies a conflict between two market influences: patients want to take the drug to get better, but they are frightened by the means of delivery. What makes marketing these technologies an even tougher business proposition for antibody therapeutics is that there is also a financial challenge: the difficulty of protecting a market for an antibody therapeutic using patents. Patents around a therapeutic target do not necessarily prevent a competitor developing a new antibody against it. Once a therapeutic target has been tested as clinically effective through the use of an antibody therapeutic, often competitor antibody developers can develop alternative therapeutics. This means that pharmaceutical companies need to look beyond the active therapeutic in order to make protein therapeutics commercially viable.

This proposition is tough, but it is also possible. There are, as I will demonstrate, success stories in injectable therapeutics - examples of how companies have managed their injectable product introductions and life cycle management. I will also examine in detail one specific route by which many pharmaceutical companies have sought to develop a competitive edge in this field.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Kevin Maynard, Business Development Director at Imprint Pharmaceuticals Ltd

Dr Kevin Maynard obtained his PhD in Biochemistry from the Queensland Institute of Medical Research at the University of Queensland, Australia and was a post-doctoral fellow at the ICRF in London. Before joining Imprint Pharma, he was a Business Development Manager at PowerJect and a Manager of Functional Genomics at AEA Technology, where he established the group as the first profitable genomics company in Europe. He is currently the Business Development Director of Imprint Pharma, a drug delivery company which focuses on the development of technologies to aid the production of complex injectable formulations.
spacer
Dr Kevin Maynard
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Premier Research Deepens Support for Oncology Sponsors By Expanding Oncology Leadership Team

As the number of next-generation oncology therapies in the clinical trial pipeline surges, Premier Research today announced three new oncology leadership team hires to strengthen the company’s expertise in the fast-growing areas of cell and gene therapies and immuno-oncology.
More info >>

White Papers

CRSF Label - Child-Resistant Blister Packs With Booklet Label

Faubel & Co. Nachfolger GmbH

This case study explains how Faubel was commissioned by a leading global pharmaceutical company to develop a label for an aluminum blister pack with 14 cavities, which was used as part of a multinational clinical trial. This label was intended to both protect infants from erroneous ingestion and facilitate use by seniors.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement